Form 4 for IQV IQVIA
Accepted 2025-10-31 00:00:00 ET · period of report 2025-10-29 · accession 0001184180-25-000006 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2025-10-31 | 2025-10-29 | IQV | BOUSBIB ARI | See Remarks, Dir | D - Sale to Iss | $220.96 | -21.0K | 807.2K | -3% | -$4.65M |
| DM | 2025-10-31 | 2025-10-29 | IQV | BOUSBIB ARI | See Remarks, Dir | S - Sale+OE | $220.33 | -56.6K | 876.6K | -6% | -$12.46M |
| D | 2025-10-31 | 2025-10-29 | IQV | BOUSBIB ARI | See Remarks, Dir | M - OptEx | $59.90 | +77.6K | 884.8K | +10% | +$4.65M |
| D | 2025-10-31 | 2025-10-29 | IQV | BOUSBIB ARI | See Remarks, Dir | M - OptEx | $59.90 | -77.6K | 50.0K | -61% | -$4.65M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-10-29 | D | D | 21,035 | $220.96 | 807,163 | D | — | — | (F1) Represents the exercise of stock appreciation rights expiring on February 2, 2026. |
| 2 | Common | Common Stock | 2025-10-29 | S | D | 3,973 | $221.97 | 828,198 | D | — | — | (F1) Represents the exercise of stock appreciation rights expiring on February 2, 2026. (F7) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $221.82 to $222.27, inclusive. |
| 3 | Common | Common Stock | 2025-10-29 | S | D | 26,128 | $221.31 | 832,171 | D | — | — | (F1) Represents the exercise of stock appreciation rights expiring on February 2, 2026. (F6) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $220.77 to $221.72, inclusive. |
| 4 | Common | Common Stock | 2025-10-29 | S | D | 4,600 | $220.11 | 858,299 | D | — | — | (F1) Represents the exercise of stock appreciation rights expiring on February 2, 2026. (F5) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $219.74 to $220.62, inclusive. |
| 5 | Common | Common Stock | 2025-10-29 | S | D | 13,741 | $219.29 | 862,899 | D | — | — | (F1) Represents the exercise of stock appreciation rights expiring on February 2, 2026. (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $218.73 to $219.66, inclusive. |
| 6 | Common | Common Stock | 2025-10-29 | M | A | 77,592 | $59.90 | 884,755 | D | — | — | (F1) Represents the exercise of stock appreciation rights expiring on February 2, 2026. |
| 7 | Common | Common Stock | 2025-10-29 | S | D | 800 | $217.58 | 883,955 | D | — | — | (F1) Represents the exercise of stock appreciation rights expiring on February 2, 2026. (F2) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.70 to $217.70, inclusive. |
| 8 | Common | Common Stock | 2025-10-29 | S | D | 7,315 | $218.32 | 876,640 | D | — | — | (F1) Represents the exercise of stock appreciation rights expiring on February 2, 2026. (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.73 to $218.70, inclusive. |
| 9 | Derivative | Stock Appreciation Right | 2025-10-29 | M | D | 77,592 | $59.90 | 50,000 | D | $59.90 · 2020-02-02 to 2026-02-02 | 77,592 Common Stock |